BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.55 CNY | +3.80% |
|
-6.56% | -20.28% |
| May. 06 | Biocytogen Enters into Evaluation and Potential Licensing Agreement with Biocopy for TCR-mimic Antibodies | CI |
| Apr. 26 | Biocytogen Pharmaceuticals' Loss Narrows in 2023 | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- The company has insufficient levels of profitability.
- With an enterprise value anticipated at 4.29 times the sales for the current fiscal year, the company turns out to be overvalued.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -20.28% | 471M | - | ||
| +33.01% | 50.85B | B- | ||
| +0.05% | 42.82B | B | ||
| +49.62% | 42.03B | A | ||
| -4.96% | 29.55B | C | ||
| +11.18% | 26.11B | B- | ||
| -21.74% | 19.13B | B | ||
| +8.55% | 13.05B | B+ | ||
| +27.91% | 12.16B | C+ | ||
| +24.30% | 12.08B | B+ |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
-
EV / Sales
Price to Book
-
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
Earnings quality
Technical analysis
ST Timing
-
MT Timing
-
LT Timing
-
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- 2315 Stock
- Ratings Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
